Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas

Stem Cell Research & Therapy

Wan-wan Wen¹  Bing-zhou Xue²  Hong-yang Zhao²  Wei Xiang²  Dong-ye Yi²  Peng Fu²  Ahmed Abdelmaksoud²  Xiao-bing Jiang²  Qing Zhang²  Nan-xiang Xiong² 

[1] Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University;Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology;

关键词: Mesenchymal stem cells (MSCs);    Gliomas;    MSC-based therapy;    Current status;    Potential challenges;   

DOI  :  10.1186/s13287-018-0977-z

来源: DOAJ

【 摘 要 】

Abstract Glioma, which accounts for more than 30% of primary central nervous system tumours, is characterised by symptoms such as headaches, epilepsy, and blurred vision. Glioblastoma multiforme is the most aggressive, malignant, and lethal brain tumour in adults. Even with progressive combination treatment with surgery, radiotherapy, and chemotherapy, the prognosis for glioma patients is still extremely poor. Compared with the poor outcome and slowly developing technologies for surgery and radiotherapy, the application of targeted chemotherapy with a new mechanism has become a research focus in this field. Moreover, targeted therapy is promising for most solid tumours. The tumour-tropic ability of stem cells, including neural stem cells and mesenchymal stem cells, provides an alternative therapeutic approach. Thus, mesenchymal stem cell-based therapy is based on a tumour-selective capacity and has been thought to be an effective anti-tumour option over the past decades. An increasing number of basic studies on mesenchymal stem cell-based therapy for gliomas has yielded complex outcomes. In this review, we summarise the biological characteristics of human mesenchymal stem cells, and the current status and potential challenges of mesenchymal stem cell-based therapy in patients with malignant gliomas.

【 授权许可】

Unknown